SKLB710

SKLB710 is a novel small molecule multi-kinase inhibitor developed by the Collaborative Innovation Center of Biotherapy (State Key Laboratory of Biotherapy) at Sichuan University. It primarily targets the Fibroblast Growth Factor Receptor (FGFR) family, including FGFR1, FGFR2, and FGFR3, as well as the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). By inhibiting these receptors, SKLB710 disrupts critical signaling pathways involved in tumor cell proliferation and angiogenesis. Preclinical studies have demonstrated that SKLB710 exhibits potent antitumor activity across various cancer models, particularly those driven by FGFR aberrations or requiring extensive vascularization for growth.